Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dacomitinib

FDA-approved product (tablet, oral), marketed as Vizimpro.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Dacomitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dacomitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dacomitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

    NCT06075615 · start 2024-09-30

    Registered record
    Registry ID
    NCT06075615
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    dacomitnib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2024-09-30
    Completion
    2026-09-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    Interventiondacomitnib
    PhaseNot recorded
    Registry statusWithdrawn

  • A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

    NCT05834348 · start 2023-06-23

    Registered record
    Registry ID
    NCT05834348
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    lorlatinib; crizotinib; brigatinib; ceritinib; alectinib; atezolizumab; bevacizumab; paclitaxel; carboplatin; docetaxel; erlotinib; gefitinib; afatinib; dacomitinib; osimertinib; pembrolizumab; nivolumab; entrectinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-06-23
    Completion
    2024-01-23
    Enrolment
    5,279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    Interventionlorlatinib; crizotinib; brigatinib; ceritinib +14 more
    PhaseNot recorded
    Registry statusCompleted

  • EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

    NCT06486142 · start 2022-09-21

    Registered record
    Registry ID
    NCT06486142
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Afatinib/Dacomitinib; Osimertinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-09-21
    Completion
    2028-09
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionAfatinib/Dacomitinib; Osimertinib
    PhasePhase 3
    Registry statusRecruiting

  • Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer

    NCT07267247 · start 2022-06-01

    Registered record
    Registry ID
    NCT07267247
    Conditions
    Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung); Drug-Related Side Effects and Adverse Reactions (MeSH Term); Egfr Tyrosine Kinase Inhibitor; Cardiotoxicity
    Interventions
    EGFR-TKI; EGFR tyrosine kinase inhibitor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-06-01
    Completion
    2024-04-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung); Drug-Related Side Effects and Adverse Reactions (MeSH Term); Egfr Tyrosine Kinase Inhibitor; Cardiotoxicity
    InterventionEGFR-TKI; EGFR tyrosine kinase inhibitor
    PhaseNot recorded
    Registry statusCompleted

  • Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

    NCT04946968 · start 2021-08-24

    Registered record
    Registry ID
    NCT04946968
    Conditions
    Advanced Solid Tumours; Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma
    Interventions
    Oral Dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-08-24
    Completion
    2027-05
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumours; Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma
    InterventionOral Dacomitinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

    NCT04609319 · start 2021-06-11

    Registered record
    Registry ID
    NCT04609319
    Conditions
    Lung Cancer
    Interventions
    Dacomitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-06-11
    Completion
    2024-05-28
    Enrolment
    307

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    InterventionDacomitinib
    PhaseNot recorded
    Registry statusCompleted

  • Korea Post Marketing Surveillance (PMS) Study of Vizimpro

    NCT04721106 · start 2021-03-07

    Registered record
    Registry ID
    NCT04721106
    Conditions
    Lung Neoplasms
    Interventions
    Vizimpro
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-03-07
    Completion
    2026-01-19
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Neoplasms
    InterventionVizimpro
    PhaseNot recorded
    Registry statusCompleted

  • Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

    NCT04504071 · start 2020-12-08

    Registered record
    Registry ID
    NCT04504071
    Conditions
    Non-small Cell Lung Cancer Metastatic; EGF-R Positive Non-Small Cell Lung Cancer
    Interventions
    Dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-12-08
    Completion
    2027-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer Metastatic; EGF-R Positive Non-Small Cell Lung Cancer
    InterventionDacomitinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Central Nervous System(CNS) Efficacy of Dacomitinib

    NCT04675008 · start 2020-12-07

    Registered record
    Registry ID
    NCT04675008
    Conditions
    Non Small Cell Lung Cancer; Brain Metastases
    Interventions
    Dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-12-07
    Completion
    2023-03-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; Brain Metastases
    InterventionDacomitinib
    PhasePhase 2
    Registry statusUnknown

  • Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

    NCT04768491 · start 2020-09-01

    Registered record
    Registry ID
    NCT04768491
    Conditions
    EGFR Activating Mutation; NSCLC Stage IV; NSCLC Stage IIIB; NSCLC, Recurrent
    Interventions
    Dacomitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-09-01
    Completion
    2024-10-31
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEGFR Activating Mutation; NSCLC Stage IV; NSCLC Stage IIIB; NSCLC, Recurrent
    InterventionDacomitinib
    PhaseNot recorded
    Registry statusUnknown

  • Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study

    NCT04397432 · start 2020-08-28

    Registered record
    Registry ID
    NCT04397432
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-08-28
    Completion
    2026-03-30
    Enrolment
    878

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • PLATFORM Study of Precision Medicine for Rare Tumors

    NCT04423185 · start 2020-08-15

    Registered record
    Registry ID
    NCT04423185
    Conditions
    Rare Tumor
    Interventions
    Almonertinib 110 MG; Dacomitinib 45 MG; Alectinib 150 MG; Crizotinib 250 MG; Pyrotinib 160/80 MG; Imatinib 400 MG; Niraparib 200/300 MG; Palbociclib 125mg; Vemurafenib 240 MG; Sintilimab 100MG; Atezolizumab 1680 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-08-15
    Completion
    2028-07-01
    Enrolment
    770

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRare Tumor
    InterventionAlmonertinib 110 MG; Dacomitinib 45 MG; Alectinib 150 MG; Crizotinib 250 MG +7 more
    PhasePhase 2
    Registry statusRecruiting

  • An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

    NCT04339829 · start 2020-08-01

    Registered record
    Registry ID
    NCT04339829
    Conditions
    Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
    Interventions
    Dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-08-01
    Completion
    2023-08-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
    InterventionDacomitinib
    PhasePhase 2
    Registry statusUnknown

  • Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

    NCT04811001 · start 2020-06-12

    Registered record
    Registry ID
    NCT04811001
    Conditions
    NSCLC
    Interventions
    Osimertinib; Dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-06-12
    Completion
    2023-12-31
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionOsimertinib; Dacomitinib
    PhasePhase 2
    Registry statusUnknown

  • Phase 2 Study of Dacomitinib in NSCLC

    NCT04027647 · start 2019-09-11

    Registered record
    Registry ID
    NCT04027647
    Conditions
    NSCLC Stage IIIB; NSCLC Stage IIIC; NSCLC Stage IV; Recurrent NSCLC; EGFR Positive Non-Small Cell Lung Cancer
    Interventions
    Dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-09-11
    Completion
    2026-03-31
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC Stage IIIB; NSCLC Stage IIIC; NSCLC Stage IV; Recurrent NSCLC +1 more
    InterventionDacomitinib
    PhasePhase 2
    Registry statusActive not recruiting